Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Japanese R/R B-precursor ALL (Horai Study)
NCT02412306Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2015
- Primary completion
- Feb 2019
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Amgen. Started Jun 2015; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT02412306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412306.